Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine

References

• MarwahaSJohnsonSSchizophrenia and employment – a reviewSoc Psychiatry Psychiatr Epidemiol200439533734915133589
   PubMed Web of Science ®Google Scholar
• KaragianisJNovickDPecenakJWorldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patientsInt J Clin Pract200963111578158819780867
   PubMed Web of Science ®Google Scholar
• LehmanAFLiebermanJADixonLBAmerican Psychiatric AssociationSteering Committee on Practice GuidelinesPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry20041612 Suppl15615000267
   PubMed Web of Science ®Google Scholar
• HerrmanHHawthorneGThomasRQuality of life assessment in people living with psychosisSoc Psychiatry Psychiatr Epidemiol2002371151051812395140
   PubMed Web of Science ®Google Scholar
• World Health OrganizationMeasuring Quality of LifeGenevaWorld Health Organization1997 Available from: http://www.who.int/mental_health/media/68.pdfAccessed November 20, 2014
   Google Scholar
• AwadAGVorugantiLNPImpact of atypical antipsychotics on quality of life in patients with schizophreniaCNS Drugs2004181387789315521791
   PubMed Web of Science ®Google Scholar
• AwadAGVorugantiLNPMeasuring quality of life in patients with schizophrenia: an updatePharmacoeconomics201230318319522263841
   PubMed Web of Science ®Google Scholar
• BobesJGarcía-PortillaPSáizPABascaránTBousoñoMQuality of life measures in schizophreniaEur Psychiatry200520suppl 3S313S31716459242
   PubMed Web of Science ®Google Scholar
• KarowANaberDSubjective well-being and quality of life under atypical antipsychotic treatmentPsychopharmacology (Berl)2002162131012107610
   PubMed Web of Science ®Google Scholar
• BoyerLBaumstarckKBoucekineMBlancJLançonCAuquierPMeasuring quality of life in patients with schizophrenia: an overviewExpert Rev Pharmacoecon Outcomes Res201313334334923763531
   PubMed Web of Science ®Google Scholar
• HunterRBarrySNegative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatmentEur Psychiatry201227643243621602034
   PubMed Web of Science ®Google Scholar
• PhillipsGAVan BruntDLRoychowdhurySMXuWNaberDThe relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidoneJ Clin Psychiatry20066791397140317017826
   PubMed Web of Science ®Google Scholar
• ThwinSSHermesELewRAssessment of the minimum clinically important difference in quality of life in schizophrenia measured by the Quality of Well-Being Scale and disease-specific measuresPsychiatry Res2013209329129623473656
   PubMed Web of Science ®Google Scholar
• WehmeierPMKlugeMSchachtAHelsbergKSchreiberWCorrelation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophreniaSchizophr Res2007911–317818617303388
   PubMed Web of Science ®Google Scholar
• LuZHuJChenC-KEffectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients switching from conventional antipsychoticsProg Neuropsychopharmacol Biol Psychiatry2007311324016843580
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders4th edWashington, DCAmerican Psychiatric Association1994
   Google Scholar
• World Health OrganizationThe ICD-10 classification of mental and behavioural disorders: diagnostic criteria for researchGenevaWorld Health Organization1993
   Google Scholar
• OverallJEGorhamDRThe Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scalingPsychopharmacol Bull1988249799
   Web of Science ®Google Scholar
• National Institute of Mental HealthClinical Global Impressions (CGI)GuyWECDEU Assessment Manual for PsychopharmacologyBethesdaUS Department of Health, Education and Welfare1976217222
   Google Scholar
• World Health OrganizationWHOQOL-BREF: Introduction, administration, scoring and generic version of the assessment, field trial versionGeneva, SwitzerlandProgramme on Mental Health1996
   Google Scholar
• KlugeMWehmeierPMDittmannRWA simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-beingPharmacopsychiatry200538161215706459
   PubMed Web of Science ®Google Scholar
• CohenJStatistical power analysis for the behavioral sciencesHillsdale, NJL. Erlbaum Associates1988
   Google Scholar
• VorugantiLCorteseLOwyeumiLSwitching from conventional to novel antipsychotic drugs: results of a prospective naturalistic studySchizophr Res2002572–320120812223251
   PubMed Web of Science ®Google Scholar
• HeinrichsDWHanlonTECarpenterWTJrThe Quality of Life Scale: an instrument for rating the schizophrenic deficit syndromeSchizophr Bull19841033883986474101
   PubMed Web of Science ®Google Scholar
• KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull19871322612763616518
   PubMed Web of Science ®Google Scholar
• MontgomerySAAsbergMA new depression scale designed to be sensitive to changeBr J Psychiatry19791344382389444788
   PubMed Web of Science ®Google Scholar
• NaberDMoritzSLambertMImprovement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugsSchizophr Res2001501–2798811378316
   PubMed Web of Science ®Google Scholar
• KleinmanLLiebermanJDubeSDevelopment and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of functionSchizophr Res20091072–327528519013769
   PubMed Web of Science ®Google Scholar
• ChenLPhillipsGJohnstonJThe relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trialBMC Psychiatry201111120322204569
   PubMed Web of Science ®Google Scholar
• EackSMNewhillCEPsychiatric symptoms and quality of life in schizophrenia: a meta-analysisSchizophr Bull20073351225123717204532
   PubMed Web of Science ®Google Scholar
• TolmanAWKurtzMMNeurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigationSchizophr Bull201238230431520624752
   PubMed Web of Science ®Google Scholar
• GuoXZhaiJWeiQEarly-stage Schizophrenia Outcome Study (ESOS) InvestigatorsNeurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up studyNeurosci Lett2011503214114621888948
   PubMed Web of Science ®Google Scholar
• KeefeRSEYoungCARockSLPurdonSEGoldJMBreierAHGGN Study GroupOne-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophreniaSchizophr Res200681111516202565
   PubMed Web of Science ®Google Scholar
• KeefeRSESweeneyJAGuHEffects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparisonAm J Psychiatry200716471061107117606658
   PubMed Web of Science ®Google Scholar
• LindenmayerJ-PKhanAIskanderAAbadMTParkerBA randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophreniaJ Clin Psychiatry200768336837917388705
   PubMed Web of Science ®Google Scholar
• FujimakiKTakahashiTMorinobuSAssociation of typical versus atypical antipsychotics with symptoms and quality of life in schizophreniaPLoS One201275e3708722615901
   PubMed Web of Science ®Google Scholar